Atai Q2 2023 Earnings Report

Atai reported Q2 2023 financial results and provided corporate updates.

Key Takeaways

Atai Life Sciences reported a net loss of $33.1 million for the three months ended June 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $227.5 million as of June 30, 2023, expected to fund operations into 1H 2026.

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia

DMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use Disorder

Cash position and committed term loan funding is expected to fund operations into 1H 2026

Announced Phase 1 trial data of DMX-1002

Previous year: -$0.24

-12.5%

Gross Profit

-$23K